Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes | Zendy

Omar Janneh | Zendy; E. Jones | Zendy; Becky Chandler | Zendy; Andrew Owen | Zendy; Saye Khoo | Zendy

Open Access

Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes

Author(s) -

Omar Janneh,

E. Jones,

Becky Chandler,

Andrew Owen,

Saye Khoo

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm353

Subject(s) - lopinavir , ritonavir , atazanavir , multidrug resistance associated protein 2 , amprenavir , efflux , pharmacology , p glycoprotein , probenecid , biology , chemistry , atp binding cassette transporter , multiple drug resistance , biochemistry , drug resistance , virology , transporter , protease , microbiology and biotechnology , enzyme , viral load , hiv 1 protease , human immunodeficiency virus (hiv) , antiretroviral therapy , gene

HIV protease inhibitors (HPIs) are an important component of highly active antiretroviral therapy. However, the activity of drug efflux transporters, such as P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRP1/MRP2), may limit intracellular drug accumulation. Drugs that inhibit the activity of drug efflux proteins may, in combination with HPIs, enhance the clinical efficacy of the drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research